Incanthera PLC (AQSE:INC) said it is delighted with the results of a permeability study for a refined formulation of its Sol anti-cancer skin cream.
Sol is a proprietary topical formulation designed to deliver into the skin an active known to prevent the conversion of solar (actinic) keratoses into skin cancer.
Against four other comparator products, Sol penetrated further into the skin and delivered the active anti-cancer ingredient deeper thereby boosting the chances of preventing a cancer forming, Incanthera said.
The study, run by the University College of London, School of Pharmacy demonstrated that the difference was statistically significant and also confirmed results from an earlier test that Sol exceeded bioequivalence or efficacy when compared with oral dosing of the same active.
In a statement, Incanthera said: “These results have exceeded the company's expectations, demonstrating unequivocally the efficacy of Sol's formulation in penetrating the skin barrier and reaching the deeper layers where an effective prevention of skin cancer could be achieved.
Incanthera said it was also delighted with the strength of the data received, which further enhances the data package to potential commercial partners.
A new patent was fiiled by the company in July to protect Sol for the prevention and treatment of solar keratoses and related cancers of the skin until 2041.
Tim McCarthy, chairman, said: "We are delighted at demonstrating the clear efficacy advantage that Sol has when compared to other approaches at delivering the active ingredient into and across the dermal barrier.
“The level at which the performance of this patented technology has exceeded expectations is extremely encouraging. “This is an important step to enable us to move forward negotiations with potential commercial partners."